1.97 USD
▼-0.06-2.96%
盘后 1.99 +0.76%
2026-09-15
市值
$111.46M
市盈率
—
EPS
-0.74
股息率
—
52 周区间
1.60 – 4.94
成交量
301.75K
Beta
3.31
目标价
10.00
52W 低 1.6052W 高 4.94
价格走势
公司简介
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey...